Pharmerica (PMC) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
UPDATE: UBS Upgrades PharMerica (PMC) to Buy
August 10, 2015 6:59 AM EDT(Updated - August 10, 2015 9:10 AM EDT)
UBS upgraded PharMerica (NYSE: PMC) from Neutral to Buy with a sum-of-the-parts valuation of $40. Analyst Steven Valiquette is positive on its faster-growing specialty business, reduced litigation overhang, and underappreciated generic pipeline.
"First, we believe the company's faster-growing specialty business which is now could hit $400 mil in revs during '15, a goal PMC mgmt originally set for '16, is now big enough to warrant a 'sum-of-the-parts' valuation vs. simply valuing the... More
